Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282015 | 0.85 | POLB (0.54) | MAPTALDH1A1CYP1A2L3MBTL1LMNA | |
| SCHEMBL16654093 | 0.81 | MAPT (0.47) | MAPTALDH1A1LMNAHPGDKMT2A | |
| SCHEMBL378458 | 0.73 | MAPT (0.96) | MAPTALDH1A1CYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL85552 | 0.72 | MAPT (1.00) | MAPTALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL223626 | 0.72 | MAPT (1.00) | MAPTALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL6607374 | 0.72 | MAPT (1.00) | MAPTALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL1851861 | 0.69 | MAPT (0.89) | MAPTALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL20836338 | 0.69 | ALDH1A1 (0.41) | MAPTALDH1A1CYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL6366966 | 0.69 | ALDH1A1 (0.41) | MAPTALDH1A1L3MBTL1LMNAHPGD | |
| SCHEMBL9213288 | 0.69 | ALDH1A1 (0.50) | MAPTALDH1A1L3MBTL1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006117556-A2 | MATERIALS AND METHODS FOR THE PHOTODIRECTED SYNTHESIS OF OLIGONUCLEOTIDE ARRAYS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2006-11-09 | — | — | WO | claimed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
| WO-2006117556-A2 | MATERIALS AND METHODS FOR THE PHOTODIRECTED SYNTHESIS OF OLIGONUCLEOTIDE ARRAYS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | MAPT 4421/4885ALDH1A1 72/4885CYP1A2 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.